Turtle Cameron
Insider CIK 1758363 · SYRE Chief Executive Officer, Director · EIDX Chief Business Officer · BBIO See Remarks · DMRA Director · ORKA Director
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| SYRE Spyre Therapeutics, Inc. | S Sale | 2026-10-01 | 2026-10-02 | 100 | $93.91 | $9.4K | 537,540 | SEC↗ |
| SYRE Spyre Therapeutics, Inc. | S Sale | 2026-10-01 | 2026-10-02 | 4,990 | $93.37 | $465.9K | 537,640 | SEC↗ |
| SYRE Spyre Therapeutics, Inc. | S Sale | 2026-10-01 | 2026-10-02 | 3,989 | $92.31 | $368.2K | 542,630 | SEC↗ |
| SYRE Spyre Therapeutics, Inc. | S Sale | 2026-10-01 | 2026-10-02 | 2,638 | $91.49 | $241.4K | 546,619 | SEC↗ |
| SYRE Spyre Therapeutics, Inc. | S Sale | 2026-10-01 | 2026-10-02 | 2,683 | $90.10 | $241.7K | 549,257 | SEC↗ |
| SYRE Spyre Therapeutics, Inc. | S Sale | 2026-10-01 | 2026-10-02 | 600 | $89.14 | $53.5K | 551,940 | SEC↗ |
| SYRE Spyre Therapeutics, Inc. | S Sale | 2026-09-01 | 2026-09-03 | 3,700 | $88.06 | $325.8K | 552,940 | SEC↗ |
| SYRE Spyre Therapeutics, Inc. | S Sale | 2026-09-01 | 2026-09-03 | 400 | $89.07 | $35.6K | 552,540 | SEC↗ |
| SYRE Spyre Therapeutics, Inc. | S Sale | 2026-09-01 | 2026-09-03 | 2,500 | $86.36 | $215.9K | 565,040 | SEC↗ |
| SYRE Spyre Therapeutics, Inc. | S Sale | 2026-09-01 | 2026-09-03 | 8,400 | $87.15 | $732.1K | 556,640 | SEC↗ |
| SYRE Spyre Therapeutics, Inc. | S Sale | 2026-09-01 | 2026-09-03 | 400 | $89.07 | $35.6K | 552,540 | SEC↗ |
| SYRE Spyre Therapeutics, Inc. | S Sale | 2026-09-01 | 2026-09-03 | 3,700 | $88.06 | $325.8K | 552,940 | SEC↗ |
| SYRE Spyre Therapeutics, Inc. | S Sale | 2026-09-01 | 2026-09-03 | 8,400 | $87.15 | $732.1K | 556,640 | SEC↗ |
| SYRE Spyre Therapeutics, Inc. | S Sale | 2026-09-01 | 2026-09-03 | 2,500 | $86.36 | $215.9K | 565,040 | SEC↗ |
| SYRE Spyre Therapeutics, Inc. | S Sale | 2026-08-03 | 2026-08-05 | 16 | $97.46 | $1.6K | 567,540 | SEC↗ |
| SYRE Spyre Therapeutics, Inc. | S Sale | 2026-08-03 | 2026-08-05 | 1,392 | $96.82 | $134.8K | 567,556 | SEC↗ |
| SYRE Spyre Therapeutics, Inc. | S Sale | 2026-08-03 | 2026-08-05 | 5,635 | $95.93 | $540.6K | 568,948 | SEC↗ |
| SYRE Spyre Therapeutics, Inc. | S Sale | 2026-08-03 | 2026-08-05 | 7,157 | $95.10 | $680.6K | 574,583 | SEC↗ |
| SYRE Spyre Therapeutics, Inc. | S Sale | 2026-08-03 | 2026-08-05 | 800 | $93.97 | $75.2K | 581,740 | SEC↗ |
| SYRE Spyre Therapeutics, Inc. | S Sale | 2026-08-03 | 2026-08-05 | 16 | $97.46 | $1.6K | 567,540 | SEC↗ |
| SYRE Spyre Therapeutics, Inc. | S Sale | 2026-08-03 | 2026-08-05 | 1,392 | $96.82 | $134.8K | 567,556 | SEC↗ |
| SYRE Spyre Therapeutics, Inc. | S Sale | 2026-08-03 | 2026-08-05 | 5,635 | $95.93 | $540.6K | 568,948 | SEC↗ |
| SYRE Spyre Therapeutics, Inc. | S Sale | 2026-08-03 | 2026-08-05 | 7,157 | $95.10 | $680.6K | 574,583 | SEC↗ |
| SYRE Spyre Therapeutics, Inc. | S Sale | 2026-08-03 | 2026-08-05 | 800 | $93.97 | $75.2K | 581,740 | SEC↗ |
| SYRE Spyre Therapeutics, Inc. | S Sale | 2026-07-01 | 2026-07-02 | 10,176 | $87.44 | $889.8K | 587,364 | SEC↗ |
| SYRE Spyre Therapeutics, Inc. | S Sale | 2026-07-01 | 2026-07-02 | 590 | $88.91 | $52.5K | 582,540 | SEC↗ |
| SYRE Spyre Therapeutics, Inc. | S Sale | 2026-07-01 | 2026-07-02 | 4,234 | $88.12 | $373.1K | 583,130 | SEC↗ |
| SYRE Spyre Therapeutics, Inc. | S Sale | 2026-06-01 | 2026-06-03 | 3,557 | $69.40 | $246.9K | 608,983 | SEC↗ |
| SYRE Spyre Therapeutics, Inc. | S Sale | 2026-06-01 | 2026-06-03 | 8,149 | $70.50 | $574.5K | 600,834 | SEC↗ |
| SYRE Spyre Therapeutics, Inc. | S Sale | 2026-06-01 | 2026-06-03 | 3,294 | $71.38 | $235.1K | 597,540 | SEC↗ |
| SYRE Spyre Therapeutics, Inc. | S Sale | 2026-05-01 | 2026-05-01 | 1,700 | $74.23 | $126.2K | 612,840 | SEC↗ |
| SYRE Spyre Therapeutics, Inc. | S Sale | 2026-05-01 | 2026-05-01 | 300 | $74.96 | $22.5K | 612,540 | SEC↗ |
| SYRE Spyre Therapeutics, Inc. | S Sale | 2026-05-01 | 2026-05-01 | 5,300 | $69.54 | $368.6K | 622,240 | SEC↗ |
| SYRE Spyre Therapeutics, Inc. | S Sale | 2026-05-01 | 2026-05-01 | 3,600 | $70.77 | $254.8K | 618,640 | SEC↗ |
| SYRE Spyre Therapeutics, Inc. | S Sale | 2026-05-01 | 2026-05-01 | 1,000 | $71.76 | $71.8K | 617,640 | SEC↗ |
| SYRE Spyre Therapeutics, Inc. | S Sale | 2026-05-01 | 2026-05-01 | 3,100 | $73.14 | $226.7K | 614,540 | SEC↗ |
| SYRE Spyre Therapeutics, Inc. | S Sale | 2026-04-01 | 2026-04-03 | 12,344 | $49.20 | $607.3K | 630,196 | SEC↗ |
| SYRE Spyre Therapeutics, Inc. | S Sale | 2026-04-01 | 2026-04-03 | 2,656 | $49.92 | $132.6K | 627,540 | SEC↗ |
| DMRA Damora Therapeutics, Inc. | A Award deriv | 2026-03-23 | 2026-03-25 | 37,313 | — | $0 | 37,313 | SEC↗ |
| SYRE Spyre Therapeutics, Inc. | S Sale | 2026-03-02 | 2026-03-03 | 5,900 | $41.73 | $246.2K | 651,640 | SEC↗ |
| SYRE Spyre Therapeutics, Inc. | S Sale | 2026-03-02 | 2026-03-03 | 9,100 | $42.49 | $386.7K | 642,540 | SEC↗ |
| SYRE Spyre Therapeutics, Inc. | S Sale | 2026-02-02 | 2026-02-04 | 14,043 | $32.87 | $461.6K | 657,540 | SEC↗ |
| SYRE Spyre Therapeutics, Inc. | S Sale | 2026-02-02 | 2026-02-04 | 957 | $31.82 | $30.5K | 671,583 | SEC↗ |
| SYRE Spyre Therapeutics, Inc. | A Award deriv | 2026-01-09 | 2026-01-13 | 528,000 | — | $0 | 528,000 | SEC↗ |
| SYRE Spyre Therapeutics, Inc. | S Sale | 2026-01-02 | 2026-01-06 | 2,191 | $31.79 | $69.7K | 672,007 | SEC↗ |
| SYRE Spyre Therapeutics, Inc. | S Sale | 2026-01-02 | 2026-01-06 | 100 | $32.39 | $3.2K | 671,907 | SEC↗ |
| SYRE Spyre Therapeutics, Inc. | S Sale | 2026-01-02 | 2026-01-06 | 12,709 | $30.47 | $387.2K | 674,198 | SEC↗ |
| SYRE Spyre Therapeutics, Inc. | S Sale | 2025-12-01 | 2025-12-03 | 10,995 | $28.73 | $315.9K | 690,912 | SEC↗ |
| SYRE Spyre Therapeutics, Inc. | S Sale | 2025-12-01 | 2025-12-03 | 4,005 | $29.83 | $119.5K | 686,907 | SEC↗ |
| SYRE Spyre Therapeutics, Inc. | S Sale | 2025-11-03 | 2025-11-05 | 16,845 | $23.66 | $398.6K | 701,907 | SEC↗ |
| SYRE Spyre Therapeutics, Inc. | S Sale | 2025-11-03 | 2025-11-05 | 28,155 | $23.13 | $651.2K | 718,752 | SEC↗ |
| ORKA Oruka Therapeutics, Inc. | A Award deriv | 2025-06-02 | 2025-06-03 | 17,500 | — | $0 | 17,500 | SEC↗ |
| SYRE Spyre Therapeutics, Inc. | A Award deriv | 2025-01-15 | 2025-01-17 | 370,000 | — | $0 | 370,000 | SEC↗ |
| SYRE Spyre Therapeutics, Inc. | A Award | 2024-02-15 | 2024-02-20 | 400 | $9.82 | $3.9K | 746,907 | SEC↗ |
| SYRE Spyre Therapeutics, Inc. | A Award deriv | 2024-02-01 | 2024-02-02 | 277,750 | — | $0 | 277,750 | SEC↗ |
| AGLE Spyre Therapeutics, Inc. | C Conversion deriv | 2023-11-24 | 2023-11-27 | 18,086 | — | $0 | 0 | SEC↗ |
| AGLE Spyre Therapeutics, Inc. | C Conversion | 2023-11-24 | 2023-11-27 | 723,440 | — | $0 | 746,507 | SEC↗ |
| AGLE Spyre Therapeutics, Inc. | A Award deriv | 2023-11-22 | 2023-11-27 | 374,000 | — | $0 | 374,000 | SEC↗ |
| EIDX Eidos Therapeutics, Inc. | D To issuer deriv | 2021-01-26 | 2021-01-28 | 53,157 | — | $0 | 0 | SEC↗ |
| EIDX Eidos Therapeutics, Inc. | D To issuer deriv | 2021-01-26 | 2021-01-28 | 9,469 | — | $0 | 0 | SEC↗ |
| EIDX Eidos Therapeutics, Inc. | U Tender | 2021-01-26 | 2021-01-28 | 50,699 | — | $0 | 0 | SEC↗ |
| BBIO BridgeBio Pharma, Inc. | M Exercise deriv | 2020-12-28 | 2020-12-29 | 6,000 | — | $0 | 56,042 | SEC↗ |
| BBIO BridgeBio Pharma, Inc. | M Exercise deriv | 2020-12-28 | 2020-12-29 | 6,000 | — | $0 | 31,766 | SEC↗ |
| BBIO BridgeBio Pharma, Inc. | M Exercise deriv | 2020-12-28 | 2020-12-29 | 7,500 | — | $0 | 255,500 | SEC↗ |
| BBIO BridgeBio Pharma, Inc. | M Exercise | 2020-12-28 | 2020-12-29 | 7,500 | $17.00 | $127.5K | 20,068 | SEC↗ |
| BBIO BridgeBio Pharma, Inc. | M Exercise | 2020-12-28 | 2020-12-29 | 6,000 | $0.34 | $2.0K | 26,068 | SEC↗ |
| BBIO BridgeBio Pharma, Inc. | M Exercise | 2020-12-28 | 2020-12-29 | 6,000 | $0.16 | $960 | 32,068 | SEC↗ |
| BBIO BridgeBio Pharma, Inc. | S Sale | 2020-12-28 | 2020-12-29 | 10,937 | $69.34 | $758.4K | 21,131 | SEC↗ |
| BBIO BridgeBio Pharma, Inc. | S Sale | 2020-12-28 | 2020-12-29 | 8,563 | $69.94 | $598.9K | 12,568 | SEC↗ |
| EIDX Eidos Therapeutics, Inc. | M Exercise deriv | 2020-12-15 | 2020-12-16 | 21,843 | — | $0 | 53,157 | SEC↗ |
| EIDX Eidos Therapeutics, Inc. | M Exercise deriv | 2020-12-15 | 2020-12-16 | 4,451 | — | $0 | 9,469 | SEC↗ |
| EIDX Eidos Therapeutics, Inc. | S Sale | 2020-12-15 | 2020-12-16 | 3,756 | $110.29 | $414.2K | 73,159 | SEC↗ |
| EIDX Eidos Therapeutics, Inc. | S Sale | 2020-12-15 | 2020-12-16 | 11,445 | $112.19 | $1.28M | 54,114 | SEC↗ |
| EIDX Eidos Therapeutics, Inc. | S Sale | 2020-12-15 | 2020-12-16 | 7,600 | $111.31 | $846.0K | 65,559 | SEC↗ |
| EIDX Eidos Therapeutics, Inc. | S Sale | 2020-12-15 | 2020-12-16 | 3,493 | $112.97 | $394.6K | 50,621 | SEC↗ |
| EIDX Eidos Therapeutics, Inc. | M Exercise | 2020-12-15 | 2020-12-16 | 21,843 | $13.20 | $288.3K | 76,915 | SEC↗ |
| EIDX Eidos Therapeutics, Inc. | M Exercise | 2020-12-15 | 2020-12-16 | 4,451 | $17.00 | $75.7K | 55,072 | SEC↗ |
| BBIO BridgeBio Pharma, Inc. | M Exercise deriv | 2020-11-25 | 2020-11-25 | 742 | — | $0 | 263,000 | SEC↗ |
| BBIO BridgeBio Pharma, Inc. | M Exercise | 2020-11-25 | 2020-11-25 | 742 | $17.00 | $12.6K | 13,310 | SEC↗ |
| BBIO BridgeBio Pharma, Inc. | S Sale | 2020-11-25 | 2020-11-25 | 742 | $47.23 | $35.0K | 12,568 | SEC↗ |
| BBIO BridgeBio Pharma, Inc. | M Exercise deriv | 2020-11-24 | 2020-11-25 | 4,258 | — | $0 | 263,742 | SEC↗ |
| BBIO BridgeBio Pharma, Inc. | M Exercise | 2020-11-24 | 2020-11-25 | 4,258 | $17.00 | $72.4K | 16,826 | SEC↗ |
| BBIO BridgeBio Pharma, Inc. | S Sale | 2020-11-24 | 2020-11-25 | 4,258 | $47.00 | $200.1K | 12,568 | SEC↗ |
| EIDX Eidos Therapeutics, Inc. | G Gift | 2020-11-11 | 2020-11-13 | 1,500 | — | $0 | 50,621 | SEC↗ |
| EIDX Eidos Therapeutics, Inc. | S Sale | 2020-11-11 | 2020-11-13 | 908 | $75.23 | $68.3K | 52,121 | SEC↗ |
| EIDX Eidos Therapeutics, Inc. | S Sale | 2020-11-11 | 2020-11-13 | 9,497 | $74.75 | $709.9K | 53,029 | SEC↗ |
| EIDX Eidos Therapeutics, Inc. | S Sale | 2020-11-11 | 2020-11-13 | 3,005 | $73.56 | $221.0K | 62,526 | SEC↗ |
| BBIO BridgeBio Pharma, Inc. | M Exercise deriv | 2020-11-05 | 2020-11-09 | 2,500 | — | $0 | 268,000 | SEC↗ |
| BBIO BridgeBio Pharma, Inc. | M Exercise | 2020-11-05 | 2020-11-09 | 2,500 | $17.00 | $42.5K | 15,068 | SEC↗ |
| BBIO BridgeBio Pharma, Inc. | S Sale | 2020-11-05 | 2020-11-09 | 2,500 | $42.05 | $105.1K | 12,568 | SEC↗ |
| EIDX Eidos Therapeutics, Inc. | M Exercise deriv | 2020-11-02 | 2020-11-03 | 5,000 | — | $0 | 75,000 | SEC↗ |
| EIDX Eidos Therapeutics, Inc. | M Exercise deriv | 2020-11-02 | 2020-11-03 | 2,500 | — | $0 | 13,920 | SEC↗ |
| EIDX Eidos Therapeutics, Inc. | M Exercise | 2020-11-02 | 2020-11-03 | 2,500 | $17.00 | $42.5K | 78,031 | SEC↗ |
| EIDX Eidos Therapeutics, Inc. | M Exercise | 2020-11-02 | 2020-11-03 | 5,000 | $13.20 | $66.0K | 75,531 | SEC↗ |
| EIDX Eidos Therapeutics, Inc. | S Sale | 2020-11-02 | 2020-11-03 | 3,146 | $71.42 | $224.7K | 65,740 | SEC↗ |
| EIDX Eidos Therapeutics, Inc. | S Sale | 2020-11-02 | 2020-11-03 | 209 | $72.10 | $15.1K | 65,531 | SEC↗ |
| EIDX Eidos Therapeutics, Inc. | S Sale | 2020-11-02 | 2020-11-03 | 9,145 | $70.44 | $644.2K | 68,886 | SEC↗ |
| BBIO BridgeBio Pharma, Inc. | M Exercise deriv | 2020-09-30 | 2020-10-02 | 6,000 | — | $0 | 62,042 | SEC↗ |
| BBIO BridgeBio Pharma, Inc. | M Exercise deriv | 2020-09-30 | 2020-10-02 | 2,500 | — | $0 | 270,500 | SEC↗ |
| BBIO BridgeBio Pharma, Inc. | M Exercise deriv | 2020-09-30 | 2020-10-02 | 6,000 | — | $0 | 37,766 | SEC↗ |
| BBIO BridgeBio Pharma, Inc. | M Exercise | 2020-09-30 | 2020-10-02 | 6,000 | $0.34 | $2.0K | 27,068 | SEC↗ |
| BBIO BridgeBio Pharma, Inc. | S Sale | 2020-09-30 | 2020-10-02 | 12,442 | $37.59 | $467.7K | 14,626 | SEC↗ |
| BBIO BridgeBio Pharma, Inc. | S Sale | 2020-09-30 | 2020-10-02 | 2,058 | $38.24 | $78.7K | 12,568 | SEC↗ |
| BBIO BridgeBio Pharma, Inc. | M Exercise | 2020-09-30 | 2020-10-02 | 6,000 | $0.16 | $960 | 21,068 | SEC↗ |
| BBIO BridgeBio Pharma, Inc. | M Exercise | 2020-09-30 | 2020-10-02 | 2,500 | $17.00 | $42.5K | 15,068 | SEC↗ |
| BBIO BridgeBio Pharma, Inc. | M Exercise deriv | 2020-09-18 | 2020-09-22 | 2,500 | — | $0 | 273,000 | SEC↗ |
| BBIO BridgeBio Pharma, Inc. | S Sale | 2020-09-18 | 2020-09-22 | 2,500 | $42.01 | $105.0K | 12,568 | SEC↗ |
| BBIO BridgeBio Pharma, Inc. | M Exercise | 2020-09-18 | 2020-09-22 | 2,500 | $17.00 | $42.5K | 15,068 | SEC↗ |
| BBIO BridgeBio Pharma, Inc. | M Exercise deriv | 2020-09-15 | 2020-09-16 | 2,500 | — | $0 | 275,500 | SEC↗ |
| BBIO BridgeBio Pharma, Inc. | S Sale | 2020-09-15 | 2020-09-16 | 2,500 | $37.06 | $92.7K | 12,568 | SEC↗ |
| BBIO BridgeBio Pharma, Inc. | M Exercise | 2020-09-15 | 2020-09-16 | 2,500 | $17.00 | $42.5K | 15,068 | SEC↗ |
| BBIO BridgeBio Pharma, Inc. | M Exercise deriv | 2020-09-11 | 2020-09-15 | 2,000 | — | $0 | 43,766 | SEC↗ |
| BBIO BridgeBio Pharma, Inc. | S Sale | 2020-09-11 | 2020-09-15 | 2,000 | $35.02 | $70.0K | 12,568 | SEC↗ |
| BBIO BridgeBio Pharma, Inc. | M Exercise | 2020-09-11 | 2020-09-15 | 2,000 | $0.34 | $680 | 14,568 | SEC↗ |
| EIDX Eidos Therapeutics, Inc. | M Exercise deriv | 2020-09-10 | 2020-09-11 | 2,500 | — | $0 | 16,420 | SEC↗ |
| EIDX Eidos Therapeutics, Inc. | S Sale | 2020-09-10 | 2020-09-11 | 2,500 | $47.00 | $117.5K | 70,531 | SEC↗ |
| EIDX Eidos Therapeutics, Inc. | M Exercise | 2020-09-10 | 2020-09-11 | 2,500 | $17.00 | $42.5K | 73,031 | SEC↗ |
| BBIO BridgeBio Pharma, Inc. | A Award | 2020-09-01 | 2020-09-02 | 2,745 | — | $0 | 12,568 | SEC↗ |
| EIDX Eidos Therapeutics, Inc. | M Exercise deriv | 2020-08-03 | 2020-08-05 | 5,000 | — | $0 | 80,000 | SEC↗ |
| EIDX Eidos Therapeutics, Inc. | S Sale | 2020-08-03 | 2020-08-05 | 6,700 | $40.25 | $269.7K | 71,031 | SEC↗ |
| EIDX Eidos Therapeutics, Inc. | M Exercise | 2020-08-03 | 2020-08-05 | 5,000 | $13.20 | $66.0K | 80,531 | SEC↗ |
| EIDX Eidos Therapeutics, Inc. | S Sale | 2020-08-03 | 2020-08-05 | 2,800 | $39.05 | $109.3K | 77,731 | SEC↗ |
| EIDX Eidos Therapeutics, Inc. | S Sale | 2020-08-03 | 2020-08-05 | 500 | $40.89 | $20.4K | 70,531 | SEC↗ |
| BBIO BridgeBio Pharma, Inc. | M Exercise deriv | 2020-06-30 | 2020-07-02 | 6,000 | — | $0 | 68,042 | SEC↗ |
| BBIO BridgeBio Pharma, Inc. | M Exercise deriv | 2020-06-30 | 2020-07-02 | 4,000 | — | $0 | 45,766 | SEC↗ |
| BBIO BridgeBio Pharma, Inc. | S Sale | 2020-06-30 | 2020-07-02 | 9,700 | $32.65 | $316.7K | 10,123 | SEC↗ |
| BBIO BridgeBio Pharma, Inc. | M Exercise | 2020-06-30 | 2020-07-02 | 4,000 | $0.34 | $1.4K | 19,823 | SEC↗ |
| BBIO BridgeBio Pharma, Inc. | M Exercise | 2020-06-30 | 2020-07-02 | 6,000 | $0.16 | $960 | 15,823 | SEC↗ |
| BBIO BridgeBio Pharma, Inc. | S Sale | 2020-06-30 | 2020-07-02 | 300 | $33.17 | $10.0K | 9,823 | SEC↗ |
| EIDX Eidos Therapeutics, Inc. | A Award | 2020-05-31 | 2020-06-05 | 376 | $41.57 | $15.6K | 75,531 | SEC↗ |
| EIDX Eidos Therapeutics, Inc. | M Exercise deriv | 2020-05-26 | 2020-05-28 | 2,500 | — | $0 | 18,920 | SEC↗ |
| EIDX Eidos Therapeutics, Inc. | S Sale | 2020-05-26 | 2020-05-28 | 2,500 | $47.00 | $117.5K | 75,155 | SEC↗ |
| EIDX Eidos Therapeutics, Inc. | M Exercise | 2020-05-26 | 2020-05-28 | 2,500 | $17.00 | $42.5K | 77,655 | SEC↗ |
| BBIO BridgeBio Pharma, Inc. | A Award deriv | 2020-05-19 | 2020-05-21 | 74,042 | — | $0 | 74,042 | SEC↗ |
| BBIO BridgeBio Pharma, Inc. | A Award deriv | 2020-05-19 | 2020-05-21 | 49,766 | — | $0 | 49,766 | SEC↗ |
| BBIO BridgeBio Pharma, Inc. | A Award deriv | 2020-05-19 | 2020-05-21 | 1,082 | — | $0 | 1,082 | SEC↗ |
| EIDX Eidos Therapeutics, Inc. | M Exercise deriv | 2020-05-01 | 2020-05-05 | 5,000 | — | $0 | 85,000 | SEC↗ |
| EIDX Eidos Therapeutics, Inc. | M Exercise | 2020-05-01 | 2020-05-05 | 5,000 | $13.20 | $66.0K | 85,155 | SEC↗ |
| EIDX Eidos Therapeutics, Inc. | S Sale | 2020-05-01 | 2020-05-05 | 7,750 | $40.52 | $314.0K | 77,405 | SEC↗ |
| EIDX Eidos Therapeutics, Inc. | S Sale | 2020-05-01 | 2020-05-05 | 1,050 | $41.23 | $43.3K | 76,355 | SEC↗ |
| EIDX Eidos Therapeutics, Inc. | S Sale | 2020-05-01 | 2020-05-05 | 1,180 | $42.56 | $50.2K | 75,175 | SEC↗ |
| EIDX Eidos Therapeutics, Inc. | S Sale | 2020-05-01 | 2020-05-05 | 20 | $43.26 | $865 | 75,155 | SEC↗ |
| BBIO BridgeBio Pharma, Inc. | M Exercise deriv | 2020-04-27 | 2020-04-29 | 2,000 | — | $0 | 278,000 | SEC↗ |
| BBIO BridgeBio Pharma, Inc. | S Sale | 2020-04-27 | 2020-04-29 | 2,000 | $32.01 | $64.0K | 9,823 | SEC↗ |
| BBIO BridgeBio Pharma, Inc. | M Exercise | 2020-04-27 | 2020-04-29 | 2,000 | $17.00 | $34.0K | 11,823 | SEC↗ |
| BBIO BridgeBio Pharma, Inc. | M Exercise deriv | 2020-04-08 | 2020-04-10 | 8,000 | — | $0 | 280,000 | SEC↗ |
| BBIO BridgeBio Pharma, Inc. | M Exercise | 2020-04-08 | 2020-04-10 | 8,000 | $17.00 | $136.0K | 17,823 | SEC↗ |
| BBIO BridgeBio Pharma, Inc. | S Sale | 2020-04-08 | 2020-04-10 | 8,000 | $27.04 | $216.3K | 9,823 | SEC↗ |
| BBIO BridgeBio Pharma, Inc. | M Exercise deriv | 2020-02-11 | 2020-02-13 | 2,000 | — | $0 | 288,000 | SEC↗ |
| BBIO BridgeBio Pharma, Inc. | M Exercise | 2020-02-11 | 2020-02-13 | 2,000 | $17.00 | $34.0K | 11,823 | SEC↗ |
| BBIO BridgeBio Pharma, Inc. | S Sale | 2020-02-11 | 2020-02-13 | 2,000 | $37.28 | $74.6K | 9,823 | SEC↗ |
| EIDX Eidos Therapeutics, Inc. | M Exercise deriv | 2020-02-03 | 2020-02-05 | 5,000 | — | $0 | 90,000 | SEC↗ |
| EIDX Eidos Therapeutics, Inc. | M Exercise deriv | 2020-02-03 | 2020-02-05 | 2,500 | — | $0 | 21,420 | SEC↗ |
| EIDX Eidos Therapeutics, Inc. | S Sale | 2020-02-03 | 2020-02-05 | 5,289 | $53.32 | $282.0K | 87,366 | SEC↗ |
| EIDX Eidos Therapeutics, Inc. | S Sale | 2020-02-03 | 2020-02-05 | 7,211 | $53.89 | $388.6K | 80,155 | SEC↗ |
| EIDX Eidos Therapeutics, Inc. | M Exercise | 2020-02-03 | 2020-02-05 | 2,500 | $17.00 | $42.5K | 92,655 | SEC↗ |
| EIDX Eidos Therapeutics, Inc. | M Exercise | 2020-02-03 | 2020-02-05 | 5,000 | $13.20 | $66.0K | 90,155 | SEC↗ |
| BBIO BridgeBio Pharma, Inc. | M Exercise deriv | 2020-01-08 | 2020-01-10 | 10,000 | — | $0 | 290,000 | SEC↗ |
| BBIO BridgeBio Pharma, Inc. | S Sale | 2020-01-08 | 2020-01-10 | 4,802 | $34.71 | $166.7K | 9,823 | SEC↗ |
| BBIO BridgeBio Pharma, Inc. | S Sale | 2020-01-08 | 2020-01-10 | 8,005 | $34.17 | $273.5K | 14,625 | SEC↗ |
| BBIO BridgeBio Pharma, Inc. | M Exercise | 2020-01-08 | 2020-01-10 | 10,000 | $17.00 | $170.0K | 22,630 | SEC↗ |
| EIDX Eidos Therapeutics, Inc. | M Exercise deriv | 2019-12-06 | 2019-12-10 | 10,000 | — | $0 | 95,000 | SEC↗ |
| EIDX Eidos Therapeutics, Inc. | S Sale | 2019-12-06 | 2019-12-10 | 8,900 | $59.43 | $528.9K | 85,155 | SEC↗ |
| EIDX Eidos Therapeutics, Inc. | S Sale | 2019-12-06 | 2019-12-10 | 400 | $56.84 | $22.7K | 94,755 | SEC↗ |
| EIDX Eidos Therapeutics, Inc. | M Exercise | 2019-12-06 | 2019-12-10 | 10,000 | $13.20 | $132.0K | 95,155 | SEC↗ |
| EIDX Eidos Therapeutics, Inc. | S Sale | 2019-12-06 | 2019-12-10 | 700 | $58.28 | $40.8K | 94,055 | SEC↗ |
| EIDX Eidos Therapeutics, Inc. | S Sale | 2019-11-20 | 2019-11-22 | 7,468 | $55.54 | $414.8K | 87,687 | SEC↗ |
| EIDX Eidos Therapeutics, Inc. | S Sale | 2019-11-20 | 2019-11-22 | 2,532 | $56.36 | $142.7K | 85,155 | SEC↗ |
| EIDX Eidos Therapeutics, Inc. | S Sale | 2019-09-04 | 2019-09-06 | 643 | $42.09 | $27.1K | 95,155 | SEC↗ |
| EIDX Eidos Therapeutics, Inc. | S Sale | 2019-09-04 | 2019-09-06 | 4,357 | $41.51 | $180.9K | 95,798 | SEC↗ |
| BBIO BridgeBio Pharma, Inc. | M Exercise deriv | 2019-07-01 | 2019-07-03 | 9,262 | — | $0 | 0 | SEC↗ |
| BBIO BridgeBio Pharma, Inc. | M Exercise deriv | 2019-07-01 | 2019-07-03 | 3,368 | — | $0 | 0 | SEC↗ |
| BBIO BridgeBio Pharma, Inc. | M Exercise | 2019-07-01 | 2019-07-03 | 3,368 | — | $0 | 3,368 | SEC↗ |
| BBIO BridgeBio Pharma, Inc. | M Exercise | 2019-07-01 | 2019-07-03 | 9,262 | — | $0 | 12,630 | SEC↗ |
| EIDX Eidos Therapeutics, Inc. | S Sale | 2019-06-04 | 2019-06-06 | 6,700 | $31.33 | $209.9K | 103,455 | SEC↗ |
| EIDX Eidos Therapeutics, Inc. | S Sale | 2019-06-04 | 2019-06-06 | 3,300 | $32.27 | $106.5K | 100,155 | SEC↗ |
| EIDX Eidos Therapeutics, Inc. | A Award | 2019-05-31 | 2019-06-06 | 1,769 | $12.01 | $21.2K | 110,155 | SEC↗ |
| EIDX Eidos Therapeutics, Inc. | A Award | 2018-11-30 | 2019-06-06 | 1,081 | $12.01 | $13.0K | 108,386 | SEC↗ |